Risk-Based Monitoring:
What Does it Mean for Clinical Study Sites?
About this webinar
The implementation of the principles of Risk-Based Monitoring (RBM) continues to be the subject of much discussion in the clinical development industry. Companies are developing strategies to focus their monitoring efforts on those aspects of a trial most critical to patient safety and data integrity. But what are the implications of these changes for clinical study sites?
This webinar will reveal some of the concerns that clinical study sites have regarding risk-based monitoring, including impacts to workload, budgets and monitoring support. The presenter will also discuss some of the popular misconceptions of what risk-based monitoring entails for study sites.
Key learning objectives
- Understand the concerns raised by sites regarding the implementation of risk-based monitoring practices
- Learn best practices in Site/CRO partnering to successfully drive efficiencies and improve oversight of patient safety and data quality
Who should attend
- Sponsor Organizations
- CROs
- Study Sites
Featured Speakers
Bob Bois
Bob Bois serves as Director, Clinical Innovation at INC Research, where he is responsible for leading project teams in the development and implementation of Risk-Based Monitoring strategies. Mr.Bois has over 20 years of experience in conducting clinical trials in varying capacities: CRA, Project Manager, Safety Program Manager, and Consultant. He has worked for both sponsor organizations (pharma and device), as well as several CROs. Mr.Bois has a bachelor’s degree in mechanical engineering with a biomedical focus from Worcester Polytechnic Institute.
Partner for this event
INC Research
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.
Related webinars
More from INC research.
Strategies for Launch Success: Considerations for a Commercially Successful Biopharmaceutical Launch in Europe
Delivering Efficiencies via the Functional Service Provider Model for Investigator Payments
What Does it Take to Successfully Execute Large, Global, Phase III Programs?
Medical Devices: Reviewing Regulatory Changes in the US and EU- Broadcast #2
The Good, the Bad, the Necessary in Rare Disease Studies
チャンス溢れるカルチャ－の中で 臨床開発のキャリアアップを目指す
Perspectives on Pediatric Trials from Investigative Sites
The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review
The Value of Strategic Alliances vs. Transactional CRO-Sponsor Relationships
Pediatric Clinical Trials – Lessons Learned the Hard Way
Regulatory Authorities and Ethics Committees: Perspectives from Europe for Pediatric Drug Development
“チャンス溢れるカルチャー”：アイエヌシー・リサーチでは、臨床開発における皆様のキャリアを伸ばすための沢山の機会があります
